LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women



Status:Completed
Conditions:Cognitive Studies, Cognitive Studies, Women's Studies
Therapuetic Areas:Psychiatry / Psychology, Reproductive
Healthy:No
Age Range:45 - 60
Updated:7/29/2018
Start Date:December 2011
End Date:April 2014

Use our guide to learn which trials are right for you!

Utilizing fMRI to Determine the Effects of Vyvanse® on Memory, Attention, and Brain Activity in Menopausal Women

This study seeks to assess the effects of lisdexamfetamine (trademark name: Vyvanse; LDX) on
executive function and prefrontal cortex activation in menopausal women ages 45-57, who
report subjective cognitive difficulties. This protocol will recruit women from Dr.
Epperson's ongoing study, Protocol #812470, to examine the impact of LDX on brain activation
during performance of cognitive tasks specifically probing prefrontal cortex function.


Inclusion Criteria:

1. Have no previous or present history of a DSM-IV psychiatric or substance dependence
disorder within the previous year, according to the Structured Clinical Interview for
Diagnosis- DSM-IV (SCID)-Non-Patient Version;

2. Are within 5 years of last menstrual period (LMP);

3. Have a follicular stimulating hormone level (FSH) of 20 IU/ml;

4. Are able to give written informed consent;

5. Must have clear urine toxicology screen upon recruitment;

6. Are fluent in written and spoken English;

7. Are right-handed;

8. Negative urine pregnancy test if still menstruating.

Exclusion Criteria:

1. Mini-mental status exam score of less than or equal to 24;

2. Presence of a psychiatric disorder within previous year or a life time history of ADHD
or psychotic disorder including bipolar disorder, schizoaffective disorder, and
schizophrenia;

3. Lifetime history of drug addiction or abuse, except nicotine;

4. Regular use of other psychotropic medication;

5. Regular use (more than once a week) of alcohol that is less than 3 drinks/day;

6. Presence of a contraindication to treatment with stimulant medication unless the
condition is controlled with medication; this would include the presence of
uncontrolled hypertension, coronary disease, atrial fibrillation, and arrhythmia;

7. History of seizures;

8. History of cardiac disease including known cardiac defect or conduction abnormality;

9. Abnormal electrocardiogram during screening;

10. Use of estrogen therapy within previous 2 months;

11. Current pregnancy or planning to become pregnant;

12. Metallic implant;

13. Claustrophobia.
We found this trial at
1
site
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials